Navigation Links
Cylene to Present Advances with Industry's Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
Date:11/16/2010

SAN DIEGO, Nov. 16, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. will present advances in the development of their first-in-class, CK2 inhibitor CX-4945, at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, to be held on November 16-19 in Berlin, Germany. CX-4945 is the first and only CK2 inhibitor to have entered clinical trials and represents an exciting new approach for the treatment for many different cancers. Three poster presentations will reveal results from the Phase I clinical trial and highlight the potential of this novel compound for combination anticancer therapies.

"We are delighted to be exhibiting so much fresh science around our flagship compound CX-4945. These scientific disclosures complement our manuscript describing the mechanism of action of CX-4945, recently accepted by the journal Cancer Research. Presentations by Cylene at premier conferences and the publication of our science by peer reviewed journals further validate CK2 as target for anticancer therapy," stated William Rice, PhD, President and CEO of Cylene Pharmaceuticals. "At the EORTC conference we will showcase the latest clinical data from patients treated with CX-4945 and also the discoveries concerning the critical roles that CK2 plays in the DNA Damage Response and EGF-Receptor pathways. These data provide a strong mechanistic rationale for the combination of CX-4945 with many agents that target these same pathways for the treatment of multiple cancers. As a company we aim to fully exploit the potential of CX-4945 in the clinic and ultimately see that it translates to real benefit for those patients and families struggling with cancer."

The presentation schedule is:

Wednesday, November 17, 2010: 12:00 PM Combined inhibition of EGFR and protein kinase CK2 synergistically blocks phosphorylation of ribosomal protein S6, induces apoptosis in cancer cells and displays enhanced antitumor activity in xenograft m
'/>"/>

SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
2. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
3. Questcor to Present at the Maxim Group Growth Conference
4. Medco to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
5. Warner Chilcott to Present at the Bank of America Merrill Lynch Credit Conference
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. WebMD to Present at the Citi 7th Annual U.S. Small/Mid Cap Conference
8. ERT to Present at Lazard Capital Markets 7th Annual Healthcare Conference on November 16, 2010
9. InfraReDx Announces Presentation of LipiScan™ Research at American Heart Association Scientific Sessions 2010
10. Philips and American Heart Association Present Fourth Annual Resuscitation Fellowship Award
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 NxStage Medical, Inc. (NASDAQ: ... dialysis products, announced today that the U.S. Food ... One™ to perform hemodialysis overnight while the patient ... hemodialysis. NxStage,s® System One is the first and ... this indication. Home nocturnal hemodialysis ...
(Date:12/22/2014)... 22, 2014   TRU-D SmartUVC LLC, producers ... robot, announced today that the General Services Administration has ... 2019.   This newly formed agreement will ... of government purchasers, including Department of Veteran Affairs and ... Security contacts purchasing solutions for the Ebola effort in ...
(Date:12/22/2014)... , Dec. 22, 2014 Cyberonics, Inc. (NASDAQ: ... the treatment and management of epilepsy, today announced it will ... Conference on Wednesday, January 14, 2015, in San ... President and Chief Executive Officer, will speak at 11:00 AM ... be accessed by clicking on the Investor Relations link on ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... March 5, 2012 Medical Care Technologies Inc. ... Special Meeting of Shareholders of the Company,s common stock held ... for lack of quorum. The adjourned Special Meeting will occur ... to provide time for the shareholders to ensure that their ...
... Wash., March 5, 2012  SCOLR Pharma, Inc. (OTCQB: SCLR) ... product information and "where to buy" details for their ... available retailers can be found on www.scolr.com ... page can be reached from the home page or ...
Cached Medicine Technology:Medical Care Technologies Inc. Announces Adjournment of Special Meeting 2Medical Care Technologies Inc. Announces Adjournment of Special Meeting 3SCOLR Pharma, Inc. Provides Product Information on Website 2
(Date:12/24/2014)... December 25, 2014 Epigenetics finds applications ... research, including oncology, drug discovery, developmental biology, and research ... as one of the most widely used techniques for ... GLOBOCAN, the prevalence of cancer is rapidly growing worldwide. ... 8.2 million cancer deaths, and 32.6 million people living ...
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
(Date:12/24/2014)... 24, 2014 Mike Billings , ... with Derek Fenwick, PT, MBA, GCS, Director of ... stem from the passing of the Improving Medicare ... In this taping of the Infinicast, the two leaders ... the Social Security Act to standardize post-acute assessment data ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- A new, injectable weight-loss ... Drug Administration. The agency on Tuesday approved Saxenda ... who are overweight and have at least one weight-related ... diabetes or high cholesterol. Patients taking the drug, ... diet and exercise regularly, the FDA noted. "Obesity ...
(Date:12/24/2014)... Steven Reinberg HealthDay Reporter ... from the American Diabetes Association (ADA) call for giving the ... to help prevent heart disease. These new standards bring ... and American Heart Association, which also recommend giving low- or ... including people with diabetes. "We agree that the decision ...
Breaking Medicine News(10 mins):Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3
... Aug. 13 As the debate over health care reform heats up, ... district has been, well, blunted. , , The billboard ... Blunt has taken $556,682 in contributions from the insurance industry. Is that ... , USAction and its Missouri affiliate, Missouri Progressive Vote Coalition, ...
... sexual assault and seeking help is difficult for anyone, but ... (LGBTQ) the thought of reporting a crime may well be ... a study in Oregon. The study, appearing in the ... found that 94 percent of respondents -- most of them ...
... , , , ... care industry moves from paper-based to electronic record-keeping, protecting confidential ... issue, Verizon is unveiling two new capabilities designed to help ... clinics, physicians, insurers and patients. , , ...
... , TORONTO, Aug. 13 /PRNewswire-FirstCall/ - Patheon Inc. (TSX: ... services to the global pharmaceutical industry, announced today that ... on Monday, September 14, 2009. , In conjunction with ... financial analysts on Monday, September 14, 2009 at 10:00 ...
... TOSU, SAGA, Japan, Aug. 13 Hisamitsu Pharmaceutical Co., Inc. ... announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust ... p.m., New York City time, on August 12, 2009, with respect ... NOVN ). , , ...
... Medical Research Council (MRC) scientists have made an important advance ... to die. The work may help scientists to eventually develop ... occur when cell death goes wrong. The research, published ... 14 August 2009) was carried out by a team of ...
Cached Medicine News:Health News:Blunted by Roy Blunt: The Billboard the Congressman Doesn't Want You to See 2Health News:Little safe haven for sexually assaulted LGBTQ victims 2Health News:Little safe haven for sexually assaulted LGBTQ victims 3Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 2Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 3Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 4Health News:Patheon Announces Date of Third Quarter 2009 Financial Results Release, Conference Call and Webcast 2Health News:Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals 2Health News:MRC scientists advance understanding of cell death 2
... A fixed pipette is ideal ... single volume. Fixed volume FInnpipettes ... advantages as other Finnpipette Digital ... Super blow-out (1-40ul), Soft-touch tip ...
10L...
... and value!, Comfortable feel and ... contoured handle , Finer control while ... action , Completely autoclavable for easy ... for recalibration , Easy-to-read precision micrometer ...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
Medicine Products: